Welcome to the 5th International Cannabinoid-Derived Pharmaceuticals Summit
Unlock the Pharmaceutical Potential of Cannabinoids
Over the last half-decade, we have witnessed game-changing developments within the cannabinoid field, driving it into a new era of rigorous research, promising clinical trials and multimillion-dollar deals. Right now, there are 50 cannabinoid therapeutic trials taking place at phases 2 and 3, pushing for approval to meet the clinical needs of patients with chronic pain, cancer, psychiatric conditions and much more. Despite these positive changes and rapid industry growth there remains key challenges to overcome for drug developers regarding the human evidence gap, funding and changing regulation – to name just a few.
The 5th International Cannabinoid-Derived Pharmaceuticals Summit is uniting drug developers, investors, solution providers and academics from around the globe working to progress the field of cannabinoid therapeutics. The Summit remains the largest conference dedicated to the development of CDPs for cancer, pain, psychiatric disorders and more, with a 3-day program focusing on demystifying FDA/EMA approval pathways, clinical trial design and commercialization, target biology and pharmacology, GMP-compliant product formulation, drug delivery, and managing the changing regulatory environment.
2022 World-Class Speaker Faculty Included:
Hear From Some Previous iCDP Attendees:
- “How about one word? Fantastic.” - Jeff Margolis, RespireRx Pharmaceuticals
- “Inspiring to be in the presence of many cannabinoid experts who all share the same passion for cannabinoid science.” – Emma Lennon, GW Pharmaceuticals
- “World class talent from biotech and cannabis research converged to shape the future of an emerging industry – Cannabinoid Medicines.” – Andrea Small-Howard, GBS Global Biopharma
- “Amazing information presented and top quality contacts for networking.” – Ted Reynolds, FlackTek Inc.